文献速递血管炎其他结缔组织病

糖皮质激素治疗与风湿性多肌痛及巨细胞动脉炎中糖尿病发病率的关联:系统综述与Meta分析

Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis.
PubMed 文献 · RMD Open · 2018-02-28

该系统综述与Meta分析纳入25篇文献,评估口服糖皮质激素治疗风湿性多肌痛(PMR)和巨细胞动脉炎(GCA)后新发糖尿病的绝对风险。PMR的糖尿病累积发病率为6%(95%CI 3%至9%),GCA为13%(95%CI 9%至17%),研究间异质性高(I²=79.1%),现有数据不足以便精确量化糖尿病风险。

要点

  • PMR患者糖皮质激素治疗后新发糖尿病累积发病率为6%(95%CI 3%至9%)
  • GCA患者新发糖尿病累积发病率为13%(95%CI 9%至17%)
  • 研究间异质性高(I²=79.1%),现有发表数据不足以精确量化糖尿病风险

核心结论

  • 该Meta分析对PMR和GCA患者中糖尿病发病率给出了看似合理的估计,但已发表数据不足以精确量化糖尿病风险。

研究设计与样本

  • 系统综述与随机效应Meta分析,检索自建库至2017年2月的文献,纳入25篇报告无既往糖尿病的PMR和/或GCA患者口服糖皮质激素后发生糖尿病的合格文献。

主要发现

  • GCA研究中的平均累积糖皮质激素剂量几乎为PMR研究的1.5倍(8.2 g vs 5.6 g),治疗时长和随访时长也略长(6.4年 vs 4.4年)。
  • PMR患者新发糖尿病的累积发病率为6%(95%CI 3%至9%),GCA患者为13%(95%CI 9%至17%)。
  • 基于英国一般人群糖尿病发病率数据,PMR患者随访4.4年、GCA患者随访6.4年的预期背景糖尿病发病率分别为4.8%和7.0%。
  • 研究间异质性高(I²=79.1%),源于研究设计、患者人群、地理区域和治疗方面的差异。
  • 关于糖尿病预测因素的信息很少。

关键数值与推荐

  • PMR新发糖尿病累积发病率:6%(95%CI 3%至9%)。
  • GCA新发糖尿病累积发病率:13%(95%CI 9%至17%)。
  • PMR随访4.4年预期背景发病率:4.8%;GCA随访6.4年预期背景发病率:7.0%。
  • 研究间异质性:I²=79.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究间异质性高(I²=79.1%),源于研究设计、患者人群、地理区域和治疗方面的差异。
  • 关于糖尿病预测因素的信息很少。
  • 已发表数据不足以精确量化糖尿病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are almost always treated with glucocorticoids (GCs), but long-term GC use is associated with diabetes mellitus (DM). The absolute incidence of this complication in this patient group remains unclear. OBJECTIVE: To quantify the absolute risk of GC-induced DM in PMR and GCA from published literature. METHODS: We identified literature from inception to February 2017 reporting diabetes following exposure to oral GC in patients with PMR and/or GCA without pre-existing diabetes. A random-effects meta-analysis was performed to summarise the findings. RESULTS: 25 eligible publications were identified. In studies of patients with GCA, mean cumulative GC dose was almost 1.5 times higher than in studies of PMR (8.2 g vs 5.6 g), with slightly longer treatment duration and longer duration of follow-up (6.4 years vs 4.4 years). The incidence proportion (cumulative incidence) of patients who developed new-onset DM was 6% (95% CI 3% to 9%) for PMR and 13% (95% CI 9% to 17%) for GCA. Based on UK data on incidence rate of DM in the general population, the expected background incidence rate of DM over 4.4 years in patients with PMR and 6.4 years in patients with GCA (follow-up duration) would be 4.8% and 7.0%, respectively. Heterogeneity between studies was high (I2=79.1%), as there were differences in study designs, patient population, geographical locations and treatment. Little information on predictors of DM was found. CONCLUSION: Our meta-analysis produced plausible estimates of DM incidence in patients with PMR and GCA, but there is insufficient published data to allow precise quantification of DM risk.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Lai LYH, Harris E, West RM, et al. Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis. RMD Open. 2018. PMID: 29531778. doi:10.1136/rmdopen-2017-000521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。